Researchers from the University of Kentucky College of Pharmacy’s Center for Pharmaceutical Science and Technology (CPST), in partnership with ChemPharma International, a Richmond-based pharmaceutical company, have received $1.2 million in funding from the National Institutes of Health (NIH) to develop treatments to be used in radiation emergencies such as after exposure to dirty bombs. “In addition to protecting the citizens of Kentucky and the U.S. from terrorist attacks, this contract is an important step in UK being recognized as ‘the place’ where new drug molecules for the treatment of nuclear or bioterrorism exposures are developed into pharmaceutical products and undergo clinical testing,” said Michael Jay, Ph.D., principal investigator of the study and director of the CPST. Full Story
About OODA Analyst
OODA is comprised of a unique team of international experts capable of providing advanced intelligence and analysis, strategy and planning support, risk and threat management, training, decision support, crisis response, and security services to global corporations and governments.